Repatha is now available for a monthly cash price of $239, through AmgenNow and GoodRx. Repatha (evolucumab) is now avaliable ...
Pharmaceutical Technology on MSN
Amgen’s Phase III data supports FDA label expansion of Repatha
Amgen received a label expansion from the FDA in August 2025, with the VESALIUS-CV data supporting this decision.
Amgen (NASDAQ:AMGN) said on Monday that it has launched its cholesterol medication, Repatha, directly to consumers in the U.S ...
Eligible Patients Can Access Repatha at Nearly 60% Discount From the List Price THOUSAND OAKS, Calif., Oct. 6, 2025 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced ...
Amgen has joined the wave of major drugmakers setting up direct-to-consumer programs amid President Donald Trump’s call for more DTC options to lower U.S. drug prices. The "AmgenNow" program, launched ...
GoodRx (Nasdaq: GDRX), the leading platform for medication savings in the U.S., today announced the availability of Repatha® ...
Amgen will offer its lipid-lowering drug Repatha directly to patients for $239 per month, representing a nearly 60% reduction ...
On the heels of an FDA label expansion in August, Amgen is touting another potential avenue to extend the value of its decade-old PCSK9 cholesterol med Repatha. In the late-stage Vesalius-CV study, ...
US biotech Amgen (Nasdaq: AMGN) has reported that its cholesterol therapy Repatha (evolocumab) hit both primary endpoints in ...
Amgen's late-stage study of human monoclonal antibody Repatha hit its dual primary targets, demonstrating it significantly reduced the risk of major adverse cardiovascular events in individuals ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback